Galectin Therapeutics (GALT) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 93.4% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -76.9% for PRLD. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $258.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | PRLD |
|---|---|---|
| Share price | $2.69 | $3.23 |
| Market cap | $271.35M | $258.63M |
| 1-day change | -4.27% | -0.77% |
| YTD return | -35.34% | +11.38% |
| 1-year return | -49.72% | +93.41% |
| 5-year return | +4.67% | -76.93% |
| EPS (TTM) | $-0.32 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $12.14M |
| Revenue growth (YoY) | — | +73.43% |
| Net income (latest FY) | $-30.84M | $-99.50M |
| Operating margin | — | -861.33% |
| Net margin | — | -819.59% |
| 52-week high | $7.13 | $6.83 |
| 52-week low | $2.03 | $1.30 |
| Distance from 52-week high | -62.27% | -52.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +172.45% |
| Average volume | 252.31K | 432.74K |
| Shares outstanding | 100.88M | 65.34M |
| Employees | 9 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed GALT by 143.1 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
GALT vs PRLD FAQ
Which is bigger, Galectin Therapeutics or Prelude Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $258.63M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, GALT or PRLD?
PRLD returned +93.41% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.